Johnson & Johnson (NYSE: JNJ) reported second-quarter 2021 financial results before the regular market hours on Wednesday. The pharmaceutical giant reported Q2 sales of $23.3 billion, up 27% year-over-year and higher than the Wall Street projection. Net income of $2.48 per share was also above the target that analysts had anticipated.
JNJ shares were trading flat immediately following the announcement. The stock has gained 7.6% since the beginning of this year.
Prior performance
Most Popular
United Parcel Service (UPS) seems on track to regain lost strength
Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic
IPO Alert: What to look for when Boundless Bio goes public
Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.
Nike (NKE) bets on innovation and partnerships to return to high growth
Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company